Genmab has signed an agreement to buy all shares of Merus at $97 per share, in an all-cash transaction valued at $8bn.

The US FDA has expanded the approval of Regeneron Pharmaceuticals' fully human monoclonal antibody, Evkeeza (evinacumab-dgnb) ...

More than two-thirds – 67% - of first responders organisations have deployed new cybersecurity protections in the last 12 ...

The 100% rate on imported, branded pharma products will not apply to drugmakers constructing manufacturing facilities in the ...

Lilly has received approval from the US Food and Drug Administration (FDA) for Inluriyo (imlunestrant) to treat advanced ...

Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.

Bucking the trend of IL-12 therapy programme failures, Imunon’s IMNN-001 was bolstered by positive translational data in ...

China rising to the top in the CGT space, the future of promising cancer vaccines in light of Trump admin's mRNA distancing, ...

Sanofi has committed an additional $625m to its venture capital arm, Sanofi Ventures, bringing its total assets under ...

Lithuania is rapidly growing as a leading force in the European life sciences scene, with over 400 life sciences companies in ...

After demonstrating that its gene therapy can slash Huntington's disease progression by 75%, Uniqure will now file for ...